1-苄基吡咯烷-3-甲酸 | 5731-18-0

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-苄基吡咯烷-3-甲酸
• 中文别名: 1-苄基-3-吡咯羧酸；1-BENZYL-DL-尾-PROLINE；N-苄基-3-吡咯烷甲酸
• 英文名称: 1-Benzyl-3-pyrrolidin-carbonsaeure
• 英文别名: 1-benzylpyrrolidin-1-ium-3-carboxylate
• CAS: 5731-18-0
• 化学式: C₁₂H₁₅NO₂
• mdl: MFCD03790980
• 分子量: 205.257
• InChiKey: RLRDUQNUBMAYDS-UHFFFAOYSA-N

物化性质

• 熔点：
  106-108 °C(Solv: methanol (67-56-1); acetone (67-64-1))
• 沸点：
  343.1±35.0 °C(Predicted)
• 密度：
  1.205±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT, HYGROSCOPIC
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H302,H317
• 危险性防范说明：
  P280

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 1-Benzyl-Pyrrolidine-3-Carboxylic Acid
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Skin sensitisation (Category 1), H317
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
R43
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H317 May cause an allergic skin reaction.
Precautionary statement(s)
P280 Wear protective gloves.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 205,26 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
1-Benzyl-Pyrrolidine-3-Carboxylic Acid
Acute Tox. 4; Skin Sens. 1; <= 100 %
H302, H317
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
1-Benzyl-Pyrrolidine-3-Carboxylic Acid
Xn, R22R43 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
No data available
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - No data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H302 Harmful if swallowed.
H317 May cause an allergic skin reaction.
Skin Sens. Skin sensitisation
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
R43 May cause sensitisation by skin contact.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  1-苄基吡咯烷-3-甲酸 在 lithium aluminium tetrahydride 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以88%的产率得到1-苄基-3-羟甲基吡咯烷
  参考文献：
  名称：

  Rifamycin derivatives

  摘要：

  公式I的新型利福霉素衍生物（包括氢醌和相应醌（C1-C4）形式）：或其盐、水合物或前药，其中：首选的R包括氢、乙酰基；L是一个连接剂，首选的连接剂元素选自图1中显示的1到5组的任意组合，但不包括其中R1为H、甲基或烷基的情况。这些创新化合物表现出有价值的抗生素特性。含有这些化合物的配方可用于控制或预防哺乳动物，包括人类和非人类的传染病。特别是，这些化合物表现出明显的抗菌活性，甚至对多重耐药菌株也有效。

  公开号：

  US20060019985A1
• 作为产物：
  描述：

  1-苄基吡咯烷-3-羧酸乙酯 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 1-苄基吡咯烷-3-甲酸
  参考文献：
  名称：

  发现新型的N-取代的脯氨酰吲唑作为有效的Rho激酶抑制剂和血管舒张剂。

  摘要：

  Rho激酶（ROCK）抑制剂在多种疾病（例如高血压，中风，哮喘和青光眼）中具有潜在的治疗适用性。在上一篇文章中，我们描述了新型ROCK I抑制剂DL0805的先导发现，它显示出强大的抑制活性（IC50 6.7μM）。在本文中，我们介绍了化合物DL0805的前导优化，从而发现了24倍和39倍活性更高的类似物4a（IC50 0.27μM）和4b（IC50 0.17μM）。此外，离体研究表明，在大鼠主动脉环中，4a和4b的血管舒张活性与批准的法舒地尔相当。

  DOI：

  10.3390/molecules22101766

文献信息

• [EN] 6H-THIENO`2, 3-B!PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH)<br/>[FR] DERIVES DE 6H-THIENO`2,3-B!PYRROLE EN TANT QU'ANTAGONISTES DE LA GONADOLIBERINE (GNRH)
  申请人：ASTRAZENECA AB

  公开号：WO2004018480A1

  公开（公告）日：2004-03-04

  The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.

  这项发明涉及一组新型噻吩-吡咯烷化合物的化学式（I）：其中：R1、R2、R3、R4和R5如规范中定义，这些化合物可用作促性腺激素释放激素拮抗剂。该发明还涉及所述化合物的药物配方、使用所述化合物的治疗方法以及所述化合物的制备方法。
• Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones
  作者：Kim M. Hutchings、Tuan P. Tran、Edmund L. Ellsworth、Brian M. Watson、Joseph P. Sanchez、H.D. Hollis Showalter、Michael A. Stier、Martin Shapiro、E. Themis Joannides、Michael Huband、Dai Q. Nguyen、Samarendra Maiti、Tingsheng Li、Jyoti Tailor、George Thomas、Chan Ha、Rajeshwar Singh

  DOI：10.1016/j.bmcl.2008.07.117

  日期：2008.9

  A novel series of bacterial topoisomerase (3-aminoquinazolinediones) inhibitors are described. The side-chain SAR against Gram-positive and Gram-negative organisms as well as DNA gyrase activity is reported.

  描述了一系列新的细菌拓扑异构酶（3-氨基喹唑啉二酮）抑制剂。据报道，针对革兰氏阳性和革兰氏阴性生物的侧链SAR以及DNA回旋酶活性。
• Angiotensin II antagonist intermediates
  申请人：Eli Lilly and Company

  公开号：US05556981A1

  公开（公告）日：1996-09-17

  This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.

  该发明提供了新颖的杂环衍生物，它们的药物配方以及它们用于拮抗哺乳动物中的血管紧张素II受体的用途。
• NOVEL COMPOUNDS
  申请人：Hauel Norbert

  公开号：US20110294775A1

  公开（公告）日：2011-12-01

  Novel compounds which are useful for treating acute pain, visceral pain, neuropathic pain, inflammatory/pain receptor-mediated pain, tumour pain and headache diseases. The following is exemplary:

  新颖的化合物，可用于治疗急性疼痛、内脏疼痛、神经痛、炎症/疼痛受体介导的疼痛、肿瘤疼痛和头痛疾病。以下是示例：
• Pyrrolidine derivatives
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US03976660A1

  公开（公告）日：1976-08-24

  Pyrrolidine derivatives which have the formula ##SPC1## Wherein R and R.sub.1 each is hydrogen, --(CH.sub.2).sub.6 COOH, --(CH.sub.2).sub.6 COO-- lower alkyl, or --(CH.sub.2).sub.6 COO benzyl and R.sub.2 is hydrogen, --CO--O--(CH.sub.2).sub.5 CH.sub.3, --CO--NH--(CH.sub.2).sub.5 CH.sub.3 --(CH.sub.2).sub.7 CH.sub.3 or --CH=CH--CH(OH)--(CH.sub.2).sub.4 --CH.sub.3, at least one of R and R.sub.1 is hydrogen and R.sub.1 and R.sub.2 are not both hydrogen, are new compounds which are useful as inhibitors of prostaglandin dehydrogenase and as potentiators of prostaglandin activity.

  吡咯烷衍生物具有以下结构式 ##SPC1## 其中R和R.sub.1分别是氢，--(CH.sub.2).sub.6 COOH，--(CH.sub.2).sub.6 COO-- 较低的烷基，或--(CH.sub.2).sub.6 COO 苄基，R.sub.2是氢，--CO--O--(CH.sub.2).sub.5 CH.sub.3，--CO--NH--(CH.sub.2).sub.5 CH.sub.3，--(CH.sub.2).sub.7 CH.sub.3或--CH=CH--CH(OH)--(CH.sub.2).sub.4 --CH.sub.3，R和R.sub.1中至少一个是氢，R.sub.1和R.sub.2不同时为氢，这些新化合物可作为前列腺素脱氢酶的抑制剂和前列腺素活性增强剂。